Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Prescribing Information

ALECENSA®(alectinib)

Avastin® (bevacizumab) [Great Britain]

Avastin® (bevacizumab) [Northern Ireland]

Esbriet® (pirfenidone)

Evrysdi®(risdiplam)

GAZYVARO® (obinutuzumab)

HEMLIBRA®(emicizumab)

Herceptin® (trastuzumab) IV

Herceptin® (trastuzumab) SC

Kadcyla®(trastuzumab emtansine)

OCREVUS®(ocrelizumab) [Great Britain]

OCREVUS®(ocrelizumab) [Northern Ireland]

Perjeta® (pertuzumab)

PHESGO® (pertuzumab/trastuzumab)

Polivy® (polatuzumab vedotin)

RoACTEMRA®(tocilizumab) RA/GCA

RoACTEMRA® (tocilizumab) pJIA/sJIA

RoACTEMRA® (tocilizumab) CRS

Rozlytrek®(entrectinib)

TECENTRIQ® (atezolizumab) Great Britain 

TECENTRIQ® (atezolizumab) Northern Ireland

 

GCA, giant cell arteritis; GPA, granulomatosis with polyangiitis; HCC Hepatocellular carcinoma; IV, intravenous; mTNBC, metastatic triple-negative breast cancer;
MPA, microscopic polyangiitis; NSCLC, Non-small-cell lung carcinoma; pJIA, polyarticular juvenile idiopathic arthritis; RA, rheumatoid arthritis; SC, subcutaneous; sJIA, systemic juvenile idiopathic arthritis; UC, urothelial carcinoma;

For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.

 

M-GB-00004866

Date of preparation: September 2021